BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4916544)

  • 1. What is the antibody specificity of LATS?
    Fagraeus A; Jonsson J; el-Kabir DJ
    J Clin Endocrinol Metab; 1970 Oct; 31(4):445-7. PubMed ID: 4916544
    [No Abstract]   [Full Text] [Related]  

  • 2. Can LATS be detected by immunofluorescence?
    Beall GN; Solomon DH; Doniach D; Roitt IM
    J Clin Endocrinol Metab; 1969 Aug; 29(8):1114-6. PubMed ID: 4895860
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-acting thyroid stimulator (LATS) in thyroid gland diseases and its relationship to the thyroid gland antibodies].
    Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
    Schweiz Med Wochenschr; 1967 Jul; 97(28):898-904. PubMed ID: 5587446
    [No Abstract]   [Full Text] [Related]  

  • 4. [Studies on the problem of a relationship between the occurrence of thyroid antibodies and LATS in hyperthyreosis].
    Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
    Med Klin; 1966 Dec; 61(52):2062-3. PubMed ID: 5999210
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
    Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
    Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence to suggest that LATS protector stimulates the human thyroid gland.
    Adams DD; Kennedy TH
    J Clin Endocrinol Metab; 1971 Jul; 33(1):47-51. PubMed ID: 5558041
    [No Abstract]   [Full Text] [Related]  

  • 7. Failure to detect long-acting thyroid stimulator with the immunofluorescence technique.
    Fedder G; Feltkamp TE
    Clin Exp Immunol; 1970 Jan; 6(1):167-8. PubMed ID: 4906525
    [No Abstract]   [Full Text] [Related]  

  • 8. LATS and thyroid autoantibodies.
    Beall GN; Solomon DH
    Clin Exp Immunol; 1968 Sep; 3(7):615-9. PubMed ID: 4883066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Simultaneous study of LATS and antimicrosomial antibodies in untreated Basedow's disease].
    Orgiazzi J; Pousset G; Durand H
    Presse Med (1893); 1971 May; 79(25):1167-8. PubMed ID: 4933634
    [No Abstract]   [Full Text] [Related]  

  • 10. ["Long-acting thyroid stimulator" (LATS) and conventional thyroid antibodies. Comparative studies].
    Depisch D; Höfer R; Schatz H
    Wien Z Inn Med; 1968; 49(11):418-22. PubMed ID: 5737591
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease.
    Földes J; Takó J; Bános C; Gesztesi E; Varga I
    Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
    Adams DD; Kennedy TH; Stewart RD
    Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LATS protector, the human thyroid stimulator.
    Adams DD
    N Z Med J; 1975 Jan; 81(531):22-3. PubMed ID: 1055310
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between the long-acting thyroid stimulator and circulating thyroid antibodies in Graves' disease.
    Pinchera A; Liberti P; De Santis R; Grasso L; Martino E; Baschieri L
    J Clin Endocrinol Metab; 1967 Dec; 27(12):1758-60. PubMed ID: 6072765
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-acting thyroid stimulator and thyroid function in relatives of patients with Graves' disease.
    Bonnyns M; Vanhaerlst L; Golstein J; Cauchie C; Ermans AM; Bastenie PA
    Clin Endocrinol (Oxf); 1973 Jul; 2(3):277-87. PubMed ID: 4128244
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunological mechanisms in thyrotoxicosis].
    Bradistilov S
    Vutr Boles; 1979; 18(2):9-16. PubMed ID: 380170
    [No Abstract]   [Full Text] [Related]  

  • 18. Thyroidal effects of injections of Graves' disease thyroid microsomes in rhesus monkeys.
    Furth ED; Dentinger M
    Endocrinology; 1971 Jul; 89(1):310-5. PubMed ID: 4103749
    [No Abstract]   [Full Text] [Related]  

  • 19. [Determination of anti-thyroid antibody].
    Shishiba Y
    Nihon Rinsho; 1979 Jun; Suppl():1511-4. PubMed ID: 226738
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in LATS and other thyoid autoantibody levels with therapy.
    Kilpatrick JA
    N Z Med J; 1974 Dec; 80(529):495-6. PubMed ID: 4532201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.